EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Fibrosis - Pipeline Review, H1 2015

  • ID: 3099695
  • Report
  • January 2015
  • 288 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AdAlta Pty Ltd.
  • Celgene Corporation
  • GenKyoTex S.A.
  • ImmuneWorks, LLC
  • Lpath, Inc.
  • Pacific Therapeutics Ltd.
  • MORE
Pulmonary Fibrosis - Pipeline Review, H1 2015

Summary

This, ‘Pulmonary Fibrosis - Pipeline Review, H1 2015’, provides an overview of the Pulmonary Fibrosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AdAlta Pty Ltd.
  • Celgene Corporation
  • GenKyoTex S.A.
  • ImmuneWorks, LLC
  • Lpath, Inc.
  • Pacific Therapeutics Ltd.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pulmonary Fibrosis Overview
Therapeutics Development
Pipeline Products for Pulmonary Fibrosis - Overview
Pipeline Products for Pulmonary Fibrosis - Comparative Analysis
Pulmonary Fibrosis - Therapeutics under Development by Companies
Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes
Pulmonary Fibrosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pulmonary Fibrosis - Products under Development by Companies
Pulmonary Fibrosis - Products under Investigation by Universities/Institutes
Pulmonary Fibrosis - Companies Involved in Therapeutics Development
AdAlta Pty Ltd.
Aeolus Pharmaceuticals, Inc.
AnaptysBio, Inc.
Angion Biomedica Corp.
Aquinox Pharmaceuticals Inc.
Auspex Pharmaceuticals, Inc.
Biogen Idec Inc.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Compugen Ltd.
Corridor Pharmaceuticals Inc.
Digna Biotech, S.L.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Five Prime Therapeutics, Inc.
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline plc
HanAll Biopharma Co., Ltd.
Histocell S.L.
iBio, Inc.
IMMD Inc.
ImmuneWorks, LLC
IntelGenx Corp.
InterMune, Inc.
Inventiva SAS
Kasiak Research Pvt. Ltd.
Kyorin Pharmaceutical Co., Ltd.
Lanthio Pharma B.V.
Lpath, Inc.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
Mesoblast Limited
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MSM Protein Technologies, Inc.
NicOx S.A.
Pacific Therapeutics Ltd.
Pharmaxis Limited
Pluristem Therapeutics Inc.
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RestorGenex Corporation
Rhizen Pharmaceuticals SA
Sanofi
Therametrics holding AG
Vectura Group plc
Pulmonary Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(pentoxifylline + acetylcysteine) - Drug Profile
ABC-294640 - Drug Profile
AEOL-10150 - Drug Profile
AM-0010 - Drug Profile
ANG-3070 - Drug Profile
ANG-3298 - Drug Profile
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis - Drug Profile
AQX-1125 - Drug Profile
BB-3 - Drug Profile
BMS-986020 - Drug Profile
BOT-191 - Drug Profile
C-301 - Drug Profile
CC-539 - Drug Profile
CC-90001 - Drug Profile
CG-1011 - Drug Profile
CGEN-25009 - Drug Profile
CKD-942 - Drug Profile
CT-140 - Drug Profile
CT-2009 - Drug Profile
DB-02901 - Drug Profile
disitertide - Drug Profile
Drug for Idiopathic Pulmonary Fibrosis - Drug Profile
Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile
FG-3019 - Drug Profile
FPA-008 - Drug Profile
GKT-137831 - Drug Profile
GR-MD-02 - Drug Profile
HC-016 - Drug Profile
HL-156FIB - Drug Profile
HR-017 - Drug Profile
IBIOCFB-03 - Drug Profile
ICG-001 - Drug Profile
IMD-1041 - Drug Profile
INT-0024 - Drug Profile
interferon gamma-1b - Drug Profile
ITMN-10534 - Drug Profile
ITMN-14440 - Drug Profile
ITMN-30162 - Drug Profile
IVA-337 - Drug Profile
IW-001 - Drug Profile
KBP-7018 - Drug Profile
lebrikizumab - Drug Profile
LP2 - Drug Profile
Lpathomab - Drug Profile
LT-0011 - Drug Profile
LY-2109761 - Drug Profile
MGN-4220 - Drug Profile
MMI-0100 - Drug Profile
Monoclonal Antibody for Idiopathic Pulmonary Fibrosis - Drug Profile
MSM-735 - Drug Profile
MSX-122 - Drug Profile
NAS-911 - Drug Profile
NCX-466 - Drug Profile
nintedanib - Drug Profile
Oligonucleotides for Respiratory and Oncology - Drug Profile
omipalisib - Drug Profile
P-007 - Drug Profile
P-17 - Drug Profile
P-529 - Drug Profile
PBF-1250 - Drug Profile
PBI-4050 - Drug Profile
phytate sodium - Drug Profile
pirfenidone - Drug Profile
PRI-724 - Drug Profile
PRM-151 - Drug Profile
PUR-1500 - Drug Profile
PXS-25 - Drug Profile
PXS-4820 - Drug Profile
PXS-5033-A - Drug Profile
PXS-64 - Drug Profile
Recombinant Human Follistatin - Drug Profile
Refacell-IPF - Drug Profile
RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis - Drug Profile
RP-6503 - Drug Profile
SAR-156597 - Drug Profile
SD-560 - Drug Profile
simtuzumab - Drug Profile
Small Molecule 1 for Chronic Respiratory Diseases - Drug Profile
Small Molecule 2 for Chronic Respiratory Diseases - Drug Profile
Small Molecule to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis - Drug Profile
Small Molecule to Inhibit NOX 1 and 4 - Drug Profile
Small Molecules to Antagonize LPA1 Receptor for Pulmonary Fibrosis - Drug Profile
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis - Drug Profile
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis - Drug Profile
SPL-334 - Drug Profile
Stem Cell Therapy for Asthma and Pulmonary Fibrosis - Drug Profile
Stem Cell Therapy for Idiopathic Lung Fibrosis - Drug Profile
Stem Cell Therapy for Pulmonary Fibrosis - Drug Profile
STX-100 - Drug Profile
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury - Drug Profile
TD-139 - Drug Profile
tipelukast - Drug Profile
tralokinumab - Drug Profile
vismodegib - Drug Profile
Pulmonary Fibrosis - Recent Pipeline Updates
Pulmonary Fibrosis - Dormant Projects
Pulmonary Fibrosis - Discontinued Products
Pulmonary Fibrosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pulmonary Fibrosis, H1 2015
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2015
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2015
Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H1 2015
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015
Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2015
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Pulmonary Fibrosis - Pipeline by Compugen Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Corridor Pharmaceuticals Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015
Pulmonary Fibrosis - Pipeline by Eli Lilly and Company, H1 2015
Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by FibroGen, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Five Prime Therapeutics, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by GenKyoTex S.A., H1 2015
Pulmonary Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by GlaxoSmithKline plc, H1 2015
Pulmonary Fibrosis - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Histocell S.L., H1 2015
Pulmonary Fibrosis - Pipeline by iBio, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by IMMD Inc., H1 2015
Pulmonary Fibrosis - Pipeline by ImmuneWorks, LLC, H1 2015
Pulmonary Fibrosis - Pipeline by IntelGenx Corp., H1 2015
Pulmonary Fibrosis - Pipeline by InterMune, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Inventiva SAS, H1 2015
Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt. Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Lanthio Pharma B.V., H1 2015
Pulmonary Fibrosis - Pipeline by Lpath, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by MedImmune, LLC, H1 2015
Pulmonary Fibrosis - Pipeline by Mesoblast Limited, H1 2015
Pulmonary Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Moerae Matrix, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by MSM Protein Technologies, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by NicOx S.A., H1 2015
Pulmonary Fibrosis - Pipeline by Pacific Therapeutics Ltd., H1 2015
Pulmonary Fibrosis - Pipeline by Pharmaxis Limited, H1 2015
Pulmonary Fibrosis - Pipeline by Pluristem Therapeutics Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Progenra, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Promedior, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015
Pulmonary Fibrosis - Pipeline by Pulmatrix, Inc., H1 2015
Pulmonary Fibrosis - Pipeline by RestorGenex Corporation, H1 2015
Pulmonary Fibrosis - Pipeline by Rhizen Pharmaceuticals SA, H1 2015
Pulmonary Fibrosis - Pipeline by Sanofi, H1 2015
Pulmonary Fibrosis - Pipeline by Therametrics holding AG, H1 2015
Pulmonary Fibrosis - Pipeline by Vectura Group plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pulmonary Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015
Pulmonary Fibrosis - Dormant Projects, H1 2015
Pulmonary Fibrosis - Dormant Projects (Contd..1), H1 2015
Pulmonary Fibrosis - Dormant Projects (Contd..2), H1 2015
Pulmonary Fibrosis - Dormant Projects (Contd..3), H1 2015
Pulmonary Fibrosis - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Pulmonary Fibrosis, H1 2015
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
AdAlta Pty Ltd.
Aeolus Pharmaceuticals, Inc.
AnaptysBio, Inc.
Angion Biomedica Corp.
Aquinox Pharmaceuticals Inc.
Auspex Pharmaceuticals, Inc.
Biogen Idec Inc.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Carolus Therapeutics, Inc.
Celgene Corporation
Chong Kun Dang Pharmaceutical Corp.
Compugen Ltd.
Corridor Pharmaceuticals Inc.
Digna Biotech, S.L.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Five Prime Therapeutics, Inc.
Galectin Therapeutics, Inc.
GenKyoTex S.A.
Gilead Sciences, Inc.
GlaxoSmithKline plc
HanAll Biopharma Co., Ltd.
Histocell S.L.
iBio, Inc.
IMMD Inc.
ImmuneWorks, LLC
IntelGenx Corp.
InterMune, Inc.
Inventiva SAS
Kasiak Research Pvt. Ltd.
Kyorin Pharmaceutical Co., Ltd.
Lanthio Pharma B.V.
Lpath, Inc.
LTT Bio-Pharma Co., Ltd.
MedImmune, LLC
Mesoblast Limited
miRagen Therapeutics, Inc.
Moerae Matrix, Inc.
MSM Protein Technologies, Inc.
NicOx S.A.
Pacific Therapeutics Ltd.
Pharmaxis Limited
Pluristem Therapeutics Inc.
Progenra, Inc.
Promedior, Inc.
ProMetic Life Sciences Inc.
Pulmatrix, Inc.
RestorGenex Corporation
Rhizen Pharmaceuticals SA
Sanofi
Therametrics holding AG
Vectura Group plc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll